Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation

Muñoz, Fernándo; Franco, Pierfrancesco; Ciammella, Patrizia; Clerico, Mario; Giudici, Mauro; Filippi, Andrea Riccardo; Ricardi, Umberto

doi:10.1186/1748-717x-2-15

Cited by 24 publications

(24 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[1,4] The origin is not clear; hypotheses include pure prostatic origin, including the basal cells of the prostatic acini, and squamous metaplasia of a prostatic urethral primary tumor. [1,3,5] Theories of histogenesis include the metaplastic transformation of adenocarcinoma, a collision-type tumor with squamous component developing from metaplastic foci, derivation from pluripotent stem cells capable of multi-directional differentiation, and clonal evolution of treated adenocarcinoma secondary to the selective pressure of therapy. [2,3] Less common is combined squamous cell carcinoma and adenocarcinoma, as in our case, with 26 cases reported in the literature.…”

Section: Discussionmentioning

confidence: 99%

“…[1,3,5] Theories of histogenesis include the metaplastic transformation of adenocarcinoma, a collision-type tumor with squamous component developing from metaplastic foci, derivation from pluripotent stem cells capable of multi-directional differentiation, and clonal evolution of treated adenocarcinoma secondary to the selective pressure of therapy. [2,3] Less common is combined squamous cell carcinoma and adenocarcinoma, as in our case, with 26 cases reported in the literature. Cases with a squamous component tended to be associated with higher grade adenocarcinomas, [4] a feature we saw in our case.…”

Section: Discussionmentioning

confidence: 99%

“…[8] Squamous metaplasia occurs during chronic prostatitis, around infarcts, or after estrogen or radiation therapy, but malignant transformation is rare. [3] Prostate cancers with squamous differentiation frequently present with lower urinary tract symptoms, often without elevation of PSA. [9] Wang [2] suggests that squamous carcinomas, in contrast to adenocarcinomas, occur more often around the prostatic urethra as opposed to the peripheral zone.…”

Section: Discussionmentioning

confidence: 99%

“…Serum prostate specific antigen, serum prostate acid phosphatase, and Gleason score are of limited value in these cases. [1,3,6] Unlike adenocarcinomas, most squamous carcinomas show negative staining for prostate specific antigen, prostate-specific acid phosphatase, P501S, and prostatic acid phosphatase and positive staining for high molecular weight keratins, such as 34βE12 and AE3. [4-6, 8, 9] Additionally, the squamous component can be differentiated by lack of staining with low molecular weight keratins, such as CAM 5.2 which will stain the glandular component.…”

Section: Discussionmentioning

confidence: 99%

“…[1,2] Median survival is 14 months. [1,3] Here, we present a case with unique findings compared with those in the literature: 1) Squamous cell and adenocarcinoma were diagnosed simultaneously; 2) The patient underwent no prior hormone treatment; 3) The squamous and adenocarcinoma components were spatially separate and on opposite sides of the prostate.…”

Section: Introductionmentioning

confidence: 87%

See 4 more Smart Citations

Squamous cell carcinoma of the prostate with concomitant adenocarcinoma in the absence of prior androgen deprivation therapy

Abbott

Kilari

Senebouttarath

et al. 2016

CRCP

View full text Add to dashboard Cite

We present a case of squamous cell carcinoma of the prostate, unique in that it was accompanied by a spatially separate focus of high-grade adenocarcinoma. Unlike previous case reports, the patient had no history of prior prostatic adenocarcinoma and had no history of treatment with antiandrogen or radiation therapy. Prostate carcinomas with squamous differentiation, while exceedingly rare, carry a poor prognosis compared to adenocarcinomas and should be considered in male patients with obstructive urinary symptoms without increased serum prostate specific antigen.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 87%

See 3 more Smart Citations

Squamous cell carcinoma of the prostate with concomitant adenocarcinoma in the absence of prior androgen deprivation therapy

Abbott

Kilari

Senebouttarath

et al. 2016

CRCP

View full text Add to dashboard Cite

show abstract

Demographics, Histopathology, and Treatment Outcomes of Squamous Cell Carcinoma of the Prostate

Gordon,

Larkins,

Siripurapu

et al. 2024

Cancer Reports

View full text Add to dashboard Cite

BackgroundSquamous cell carcinoma of the prostate (SCCP) is a neoplasm that comprises fewer than 1% of all primary prostate cancer diagnoses. Given its rarity, there is a paucity of data regarding the treatment of this disease. The limited literature points to the potential of local therapy in conjunction with chemotherapy to improve patient mortality.MethodsUsing the National Cancer Initiative's Surveillance, Epidemiology, and End Results (SEER) database, a retrospective review of patients diagnosed with primary SCCP between 2000 and 2018 was performed. Patient demographics, tumor characteristics, and patient outcomes based on treatment modality were analyzed. Univariate and survival analyses were conducted with p < 0.05 indicating statistical significance.ResultsA total of 66 patients were identified. Five‐year overall survival (5y OS) was 24%; mean and median survival were 2.2 years (1.8, 2.7) and 1.2 years (0.3, 2.1), respectively. Patients with Grade I or Grade II disease had an increased 5y OS of 55% (27%, 83%). In comparison, 5y OS was 13% (−2%, 29%) for patients with Grade III and Grade IV disease (p = 0.017). Analysis of 5y OS based on disease histology revealed patients with papillary SCC had a 5y OS of 50% [9.2%, 91%], compared to 21% [9%, 34%] for patients with SCC, not otherwise specified and 0% for those with lymphoepithelial carcinoma (p = 0.048). Analysis of 5y OS stratified by treatment modality revealed no statistically significant change with any treatment (surgery, radiotherapy, and chemotherapy). No difference in 5y OS was seen between those treated with radical prostatectomy versus external beam radiation therapy.ConclusionsThe literature on SCCP remains sparse; the rarity of this disease limits analysis. While the investigation undertaken in this paper does not find any change in 5y OS regardless of treatment modality, the variation in 5y OS based on histologic classification of SCCP points to a potential route for the future treatment of this disease.

show abstract

Successful treatment with DCF chemotherapy and radiotherapy for primary squamous cell carcinoma of the prostate

et al. 2021

View full text Add to dashboard Cite

Introduction: Primary squamous cell carcinoma of the prostate is an extremely rare tumor with poor prognosis. Squamous cell carcinoma of the prostate is estimated to comprise less than 1% of all prostate carcinomas. We report herein a case with clinical response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy with radiotherapy, in a patient with metastatic squamous cell carcinoma of the prostate. Case presentation: A 74-year-old man consulted with frequent urination. The prostate-specific antigen level was 1.62 ng/mL. Multiparametric magnetic resonance imaging showed prostate imaging and reporting and data system category 5 for the whole prostate and biopsy was performed. The pathological diagnosis was pure squamous cell carcinoma of the prostate. fluorodeoxyglucose positron emission tomography showed fluorodeoxyglucose accumulation in the whole prostate and multiple pelvic lymph nodes. Four cycles of docetaxel, cisplatin, and 5-fluorouracil regimen were administrated along with radiotherapy. The patient showed a marked response with no major adverse events. Conclusion:The present case suggests the potential of docetaxel, cisplatin, and 5fluorouracil chemotherapy with radiotherapy for squamous cell carcinoma of the prostate.

show abstract

Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation

Abstract: Background: Carcinoma of the prostate gland is the most frequent malignant tumour affecting male population. While the large majority of tumours is represented by adenocarcinoma, pure squamous cell carcinoma comprises only 0,5-1% of all prostate neoplastic lesions.

Cited by 24 publications

References 32 publications

Squamous cell carcinoma of the prostate with concomitant adenocarcinoma in the absence of prior androgen deprivation therapy

Squamous cell carcinoma of the prostate with concomitant adenocarcinoma in the absence of prior androgen deprivation therapy

Demographics, Histopathology, and Treatment Outcomes of Squamous Cell Carcinoma of the Prostate

Successful treatment with DCF chemotherapy and radiotherapy for primary squamous cell carcinoma of the prostate

Contact Info

Product

Resources

About